Sartorius Aktiengesellschaft (OTCMKTS:SARTF – Get Free Report) announced its quarterly earnings data on Monday. The company reported $1.11 earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $967.37 million during the quarter. Sartorius Aktiengesellschaft had a net margin of 2.50% and a return on equity of 7.69%.
Sartorius Aktiengesellschaft Price Performance
Sartorius Aktiengesellschaft stock remained flat at $205.97 during trading on Wednesday. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.13 and a current ratio of 2.02. Sartorius Aktiengesellschaft has a 12 month low of $175.93 and a 12 month high of $313.00. The stock’s 50 day moving average price is $206.55 and its 200-day moving average price is $205.79.
Analyst Ratings Changes
Several research analysts have weighed in on the stock. Wolfe Research raised shares of Sartorius Aktiengesellschaft to a “strong-buy” rating in a research note on Thursday, November 14th. Guggenheim raised shares of Sartorius Aktiengesellschaft to a “strong-buy” rating in a research note on Thursday, December 19th.
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers.
Recommended Stories
- Five stocks we like better than Sartorius Aktiengesellschaft
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Intel Surges on M&A Talks: Rally Beginning or Just a Headfake?
- How to Invest in the Best Canadian Stocks
- Solid Biosciences Soars 32% on Trial Data: 189% Upside from Here?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Up Nearly 1000%, Can AppLovin Keep Delivering for Investors?
Receive News & Ratings for Sartorius Aktiengesellschaft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius Aktiengesellschaft and related companies with MarketBeat.com's FREE daily email newsletter.